APL share price, P/E, ROE & financials

On 6 Nov 2026, Asston Pharmaceuticals was priced at ₹141.10, or 28.7× trailing earnings, against an industry P/E of 28.7×. Sales and net profit grew 57% and 54% a year over 3 years; its ROCE of 12% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, though net profit is above operating profit, which points to a one-off gain. Debt is 0.13× equity. It is listed on an SME platform with a market cap of ₹154 Cr, ranked 102nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 67% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Mar 2026.How we calculate this

past year

Open: ₹136.50
Day high: ₹144.95
Day low: ₹134.00
Prev. close: ₹138.80
Volume: 18K

Health check

2 good · 1 fair · 2 to check

ReturnsAhead
+67.0% over a year, better than 6 of 7 peers.
Price tagDistorted
A one-off gain inflates profit, so P/E isn’t comparable right now.
GrowthStrong
Sales +57.3%, profit +54.1% a year over 3 years.
ProfitabilityWeak
ROCE 12.2% vs peer median 17.9%.
Balance sheetFair
Debt 0.13× equity, interest covered 8.4×, Piotroski 4 of 9.
Red flags3 to check
Quarterly profit down 75.3% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹154 Cr, #102 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Mar 2026: sales ₹25 Cr · profit ₹4 Cr

Market cap: ₹154 Cr; Small cap
P/E: 28.7; Industry 28.7
Price to book: 3.09; Peers 4.99
Dividend yield: 0.00%
ROE: 15.5%; Peers 14.7%
ROCE: 12.2%; Peers 17.9%
Debt to equity: 0.13; Debt ₹5.11 Cr
EPS (TTM): ₹4.92
OPM (TTM): −29.9%; Net margin 15.2%
Sales growth: +10.9%; Latest quarter vs a year ago
Profit growth: −75.3%; Latest quarter vs a year ago
Price to sales: 6.05; EV/EBITDA −240.4

Risks to check

Quarterly profit down 75.3% on a year ago.
Net profit is above operating profit, so a one-off gain is likely flattering earnings.
Interest coverage of only 1.0×.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Asston Pharmaceuticals

Asston Pharmaceuticals Limited manufactures pharmaceutical products in India, West Africa, South Africa, and Asian countries. The company provides tablets, such as aceclofenac, albendazole, aminophylline, artemether and lumefantrine, ascorbic acid chewable, azithromycin, b-complex, calcium, cholecalciferol with folic acid, cefixime, cetirizine, ciprofloxacin, co-trimoxazole, cyproheptadine, dexamethasone, diclofenac, ferrous sulphate, folic acid, glucose,…

Headquarters: Navi Mumbai
Employees: 42
Sector: Healthcare
ISIN: INE0SJX01015
Website: asstonpharmaceuticals.com

Price range

52 weeks

₹60.00₹153.40

Today

₹134.00₹144.95

Avg volume (3M): 40.2K
1-year return: plus 67.0%
From 52-week high: minus 8.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
APLAsston Pharmaceuticals	141.10	plus 1.66%	154	28.7	3.09	12.2%	15.5%	−29.9%	57.3%	54.1%	0.00%	plus 67.0%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore · latest reported Mar 26

SalesSelect a row below to chart it

₹ Cr	Mar 25	Mar 26
	9.1	10.1
	5.9	12.9
	3.2	−2.8
	35.0%	−27.8%
	−0.1	4.6
	0.5	0.4
	0	0.3
	2.6	1.2
	23.7%	60.4%
	2	0.5
	2.29	1.14

Jun 25, Sep 25, Dec 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +57.3%
Profit CAGR 3Y: +54.1%
ROE: 15.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
6.5	15.6	25	25.5
–	+138.4%	+60.6%	+1.7%
4.9	12.8	18.6	24.9
1.6	2.8	6.4	0.6
24.6%	17.8%	25.7%	2.4%
0.5	0	−0.6	5.9
0.7	0.9	0.8	0.6
0	0.1	0	0.3
–	–	0.1	−1
1.4	1.8	5	4.6
25.2%	25.1%	23.2%	15.9%
1.1	1.4	3.9	3.9
–	+28.7%	+183.2%	+0.3%
1.24	1.60	4.53	–

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
0.7	0.8	6.3	8.5
1.3	5.6	4.8	30.3
5.2	6.8	7.3	5.1
6.5	7	9.8	7.7
13.7	20.3	28.1	51.6
1.1	1.1	1	10.7
0.7	0.7	–	–
0.1	0	0.2	1.3
11.8	18.5	27	39.7
13.7	20.3	28.1	51.6

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−0.3	−3.8	−0	−10.2
−0.9	−0	0.7	−9.9
1.2	3.7	−0.5	21.2
−0	−0.1	0.2	1.1
−0.3	−0	−0	−10.1
−0.6	−3.8	−0	−20.2

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you